Clinical trial aims to side-step side-effects with state-of-the-art radiotherapy 16 Feb 2020 A major clinical trial has shown that changing the way radiotherapy is delivered could significantly reduce the side effects associated with radiotherapy treatment for prostate cancer. Find out more Show/Hide
The ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in Scotland 13 Jan 2020 The Institute of Cancer Research, London, strongly welcomes the recommendation by the Scottish Medicines Consortium (SMC) to make the prostate cancer drug abiraterone available to men with advanced prostate cancer as first-line treatment on the NHS in Scotland. Find out more Show/Hide
Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer 02 Dec 2019 A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. Find out more Show/Hide
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer 30 Sep 2019
ESMO 2019: Modern chemotherapy drug better than second targeted hormone therapy against resistant prostate cancer 30 Sep 2019
ESMO 2019: Largest ever trial in postoperative prostate cancer patients confirms that men can be spared radiotherapy after surgery 27 Sep 2019
Targeted prostate cancer radiotherapy technique could cut treatment time from two months to two weeks 17 Sep 2019